Characterization of immune response and duration of protection in buffaloes immunized with haemorrhagic septicaemia vaccines

Chandrasekaran, S; Kennett, L.; Yeap, P.C.; Muniandy, N.; Rani, Bakthavatsalam Sandya; Mukkur, T.K.S.

doi:10.1016/0378-1135(94)90102-3

Cited by 23 publications

(21 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…vaccination paralleled the clinical response (increased rectal temperature and demeanor score), indicating that the attenuated bacteria persisted long enough to promote an inflammatory response. However, there was no corresponding increase in either the serum IgG or IgM concentration during the days following primary vaccination, in agreement with the observations of others (2,9,17), who reported only a gradual increase in serum IgG titers over a 6-to 10-week period after vaccination with oil-adjuvant vaccine (which may allow a slow release of antigen). The reasons for this in the present work may have been that the aroA derivative was too attenuated and cleared too rapidly to have stimulated a clear humoral response to the primary vaccination, and it may be beneficial in future to test the efficacy of other attenuating mutations using the animal model described in this study.…”

Section: Discussionsupporting

confidence: 92%

“…The relative contributions of cellular and humoral immunity to long-term protection have not been established, but a strong correlation between the induction of humoral immunity and active protection in buffaloes vaccinated with killed whole-cell vaccines has been reported (2), and thus, the humoral response to vaccination was the focus of the present work. The principal antibody response in buffaloes vaccinated with oil-adjuvant vaccines or formalin-killed bacteria was the IgG class, with only mild IgM responses reported (2,17). Our data were essentially in agreement with this, although a clear IgM response to the i.m.…”

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Efficacy of Vaccination of Calves against Hemorrhagic Septicemia with a Live aroA Derivative of Pasteurella multocida B:2 by Two Different Routes of Administration

et al. 2005

View full text Add to dashboard Cite

Two groups of four calves each were immunized either intramuscularly (i.m. vaccinated) or intranasally (i.n. vaccinated) at 2 and 6 weeks of age with ca. 10 9 CFU of a derivative of P. multocida serotype B:2 strain 85020 containing a deletion in the aroA gene (strain JRMT12). Both groups of calves and three unvaccinated control calves were challenged subcutaneously at 8 weeks of age with ca. 10 7 CFU of the wild-type 85020 strain. The first and second vaccinations caused a significant pyrexia and increase in the mean demeanor score (P < 0.05) in i.m. but not i.n. vaccinated calves. Serum agglutinating activity against whole cells of P. multocida strain 85020 and immunoglobulin G antibody concentrations increased after the second vaccination in i.m. but not in i.n. vaccinated animals, and this difference was statistically significant (P < 0.05). Concentrations of serum amyloid A (SAA) increased significantly 3 h after both the primary (P < 0.05) and booster (P < 0.001) i.m. vaccinations, but not in i.n. vaccinated calves. All four i.m. vaccinated calves were solidly immune to challenge with wild-type P. multocida B:2. However, the mean rectal temperatures, demeanor scores, and serum SAA concentrations of i.n. vaccinated and control calves increased significantly (P < 0.01). Three i.n. vaccinated and two control calves were killed for humane reasons within 14 h postchallenge, and postmortem examination revealed pathological lesions consistent with hemorrhagic septicemia. These data showed that the aroA mutant strain, given i.m. as two doses 4 weeks apart, acted as an effective live-attenuated vaccine strain to protect calves against challenge with the virulent parent strain.Hemorrhagic septicemia (HS) caused by infection with Pasteurella multocida serotype B:2 is a commonly fatal systemic disease of cattle and buffaloes in countries of South and Southeast Asia (3, 22). The disease is peracute, having a short clinical course involving severe depression, pyrexia, submandibular edema, and dyspnea, followed by recumbency and death. Some control is achieved with alum-precipitated or oil adjuvant broth bacterins injected subcutaneously, but these vaccines have the disadvantage of providing only short-term immunity (4 to 6 months and up to 1 year for alum adjuvant and oil adjuvant vaccines, respectively) (21), and the high viscosity of oil adjuvant vaccines makes them unpopular among field users. The disease remains a significant obstacle to sustainable agriculture in the region, and in attempts to elicit longer-term immunity, live vaccines have been developed (14), although they have been ill defined and of questionable safety. On the other hand, a marker-free aroA deletion derivative (strain JRMT12) of a virulent field isolate of P. multocida B:2 (strain 85020) obtained from Sri Lanka has been shown to be attenuated and to confer a high degree of protection when used as a live vaccine in a mouse model of hemorrhagic septicemia (19). The construct is particularly suited to be a live vaccine candidate, as it possesses no...

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 87%

Efficacy of Vaccination of Calves against Hemorrhagic Septicemia with a Live aroA Derivative of Pasteurella multocida B:2 by Two Different Routes of Administration

et al. 2005

View full text Add to dashboard Cite

show abstract

“…The apparent association of different mean IgM titers with groups preceded any differences in treatment and was coincidental. There was no significant increase in either serum IgG or IgM concentrations during the days following primary vaccination with any of the vaccine doses, in agreement with our previous work (12) and with the observations of others (4,13,20). If anti-P. multocida serogroup A:3 IgM antibody was present, it may have reacted with the vaccine dose, a phenomenon reported previously (2), thereby reducing the titer, as seen at day 14, and thus minimizing the humoral response to vaccination.…”

Section: Discussionsupporting

confidence: 93%

Safety and Protective Efficacy of Intramuscular Vaccination with a LivearoADerivative ofPasteurella multocidaB:2 against Experimental Hemorrhagic Septicemia in Calves

et al. 2007

View full text Add to dashboard Cite

Three groups of five calves, namely, V1, V2, and V3, were immunized intramuscularly at 4 and 8 weeks of age with ca. 10 9 , 10 8 , and 10 7 CFU, respectively, of a derivative of Pasteurella multocida B:2 wild-type strain 85020 containing a deletion in the aroA gene (strain JRMT12). The first and second vaccinations resulted in significantly (P < 0.01) higher rectal temperature responses in groups V1 and V2 than in group V3. Serum immunoglobulin M (IgM) and IgG titers did not increase in any group until after the second vaccination and were then significantly higher in groups V1 and V2 than in group V3 (P ‫؍‬ 0.001 for both IgM and IgG). All vaccinated groups and three unvaccinated challenge control calves (group CC) were injected subcutaneously at 10 weeks of age with ca. 10 7 CFU of strain 85020. Vaccinated calves survived the challenge, but two CC animals developed clinical disease and were killed for humane reasons. After challenge, mean serum amyloid A concentrations were significantly higher (P < 0.001) in the CC group than in the vaccinated groups. Postmortem examination revealed that calves in the CC group showed the most extensive range of bacteriologically positive tissues and gross and histopathological lesions. Overall, a clear dose-dependent response was present, with those receiving a higher vaccine dose being less affected clinically, bacteriologically, and pathologically by the wild-type challenge. The V2 treatment appeared to give the best combination of high immune response, protection, and safety.

show abstract

“…Effective vaccines such as alumprecipitated and oil adjuvant vaccine have been developed (Chandrasekaran et al, 1994) but difficulties in vaccine administration lead to low vaccination coverage and disease outbreaks (Saharee et al, 1993). However, animals that survived natural infection were found to have stronger immunity than vaccinated animals and the immunity was maintained for several years (Carter and De Alwis, 1989).…”

Section: Introductionmentioning

confidence: 99%

Protective effect following intranasal exposure of goats to live Pasteurella multocida B:2

Zamri‐Saad

Ernie

Sabri

2006

Trop Anim Health Prod

View full text Add to dashboard Cite

This study aimed to determine the effect of intranasal exposure to low doses of Pasteurella multocida B:2 on survival of goats challenged with high doses of the same organism. Eighteen goats were selected and divided into three groups. Goats of group 1 were exposed intranasally twice, with a two-week interval, to 7 x 10(6) cfu/ml of live P. multocida B:2. Goats of group 2 were not exposed to P. multocida B:2 but were kept together with the exposed group 1. Goats of group 3 remained as unexposed controls and were kept separated from the other two groups. Serum samples were collected at weekly intervals to determine the antibody levels. At week 5 post exposure, all goats were challenged subcutaneously with 3.7 x 10(10) cfu/ml of live P. multocida B:2. Following challenge exposure, 8 (67%) goats (4 goats from each of groups 1 and 2) were killed owing to haemorrhagic septicaemia. Four goats were killed peracutely within 48 h post challenge, while the other four goats were killed acutely between 2 and 4 days post challenge. None of the goats of group 3 were killed for haemorrhagic septicaemia. Goats of groups 1 and 2 showed significantly (p < 0.05) higher antibody levels following the first intranasal exposure to P. multocida B:2. However, only group 1 retained the significantly (p < 0.05) high antibody levels following a second intranasal exposure, and remained significantly (p < 0.05) higher than groups 2 and 3 at the time of challenge. P. multocida B:2 was successfully isolated from various organs of goats that were killed between 1 and 4 days post challenge.

show abstract

Characterization of immune response and duration of protection in buffaloes immunized with haemorrhagic septicaemia vaccines

Cited by 23 publications

References 2 publications

Efficacy of Vaccination of Calves against Hemorrhagic Septicemia with a Live aroA Derivative of Pasteurella multocida B:2 by Two Different Routes of Administration

Efficacy of Vaccination of Calves against Hemorrhagic Septicemia with a Live aroA Derivative of Pasteurella multocida B:2 by Two Different Routes of Administration

Safety and Protective Efficacy of Intramuscular Vaccination with a LivearoADerivative ofPasteurella multocidaB:2 against Experimental Hemorrhagic Septicemia in Calves

Protective effect following intranasal exposure of goats to live Pasteurella multocida B:2

Contact Info

Product

Resources

About